-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yimaitong edited and sorted, please do not reprint
without authorization.
On December 26, 2022, the official website of the National Health Commission issued an announcement to rename the novel coronavirus pneumonia to the new coronavirus infection
.
This article summarizes recent guidelines and consensus documents related to the diagnosis and treatment of new coronavirus infection and health management for everyone to learn
.
Diagnosis and treatment plan for new coronavirus infection 01
Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)
Since 2022, the Omicron variant of the new coronavirus has gradually become an absolute dominant epidemic strain, and its transmissibility and immune evasion ability have been significantly enhanced, but its pathogenicity has been significantly weakened
.
In order to further scientifically and standardize the diagnosis and treatment of new coronavirus infection, we organized experts to revise the relevant content of the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9)" to form the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)
".
Link:
https://guide.
medlive.
cn/guideline/27703
Diagnosis and Treatment Plan for Novel Coronavirus Infection in Xiangya Hospital of Central South University (Trial)
This article mainly introduces the clinical manifestations, diagnosis, examination, classification management, drug treatment, respiratory support treatment, nosocomial infection management and discharge criteria and life guidance
of novel coronavirus infection.
Link:
https://guide.
medlive.
cn/guideline/27688
Shanghai Novel Coronavirus Infection Diagnosis and Treatment Standards and Graded Diagnosis and Treatment Process (Primary Simplified Version)
The Shanghai Novel Coronavirus Disease Clinical Treatment Expert Group and the National Center for Infectious Diseases have jointly rewritten the 2022 Shanghai Novel Coronavirus Infection Diagnosis and Treatment Standards and Graded Diagnosis and Treatment Procedures (Simplified Version of Primary Medical Institutions) on the basis of the National Health Commission's Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9).
Link:
https://guide.
medlive.
cn/guideline/27681
Recommendations and Appropriate Technologies for Primary Diagnosis and Treatment of Novel Coronavirus Infection in Peking Union Medical College Hospital (First Edition[2023.
1.
3])
Peking Union Medical College Hospital adheres to the principles of evidence-based, concise and clinically operable, and has compiled a basic version of the diagnosis and treatment plan recommendations
.
Link:
https://guide.
medlive.
cn/guideline/27680
Peking Union Medical College Hospital Department of Respiratory and Critical Care Medicine Reference Plan for the Diagnosis and Treatment of New Coronary Pneumonia (December 2022 Edition)
This program aims to enhance the understanding of respiratory and critical care physicians on novel coronavirus infection and its critical diseases, provide a basis for clinical decision-making, promote standardized diagnosis and treatment, and improve the level of
patient treatment.
Link:
https://guide.
medlive.
cn/guideline/27679
Antiviral therapy 01
Clinical Pharmacy Guidelines for Antiviral Treatment for Novel Coronavirus Pneumonia (Updated Version)
Guangdong Pharmaceutical Association once again organized pharmacy and clinical experts to refer to the latest research results at home and abroad, and combined with the COVID-19 treatment experience of Guangdong Province, to update the previous "Clinical Pharmacy Guidelines for Antiviral Treatment of Novel Coronavirus Pneumonia", in order to further promote the clinical rational application of new coronavirus pneumonia antiviral drugs, effectively improve the level of drug treatment, and ensure the safety
of patients.
Link:
https://guide.
medlive.
cn/guideline/27618
Azvudine treatment of novel coronavirus pneumonia Henan pharmaceutical expert consensus
Azvudine is an oral small molecule antiviral drug completely independently developed and patented in China, which is more suitable for the medical needs
of the new crown virus impact in the post-epidemic era.
This consensus was officially released on December 17, 2022 at the opening ceremony of the 2022 Henan Pharmaceutical Association Academic Annual Conference, aiming to correctly guide the rational application
of azvudine in clinical practice.
Link:
https://guide.
medlive.
cn/guideline/27632
Clinical pharmacy guidelines for the use of nematevir/ritonavir tablets (Paxlovid) in cardiovascular patients in Guangdong Province
Patients with cardiovascular disease and other risk factors such as diabetes, high blood pressure, chronic kidney disease and smoking make up a large proportion
of high-risk groups.
Many commonly used drugs in cardiovascular patients have clinically significant interactions with Paxlovid, so the "Pharmaceutical Guidelines for the Use of Nematevir/Ritonavir Tablets (Paxlovid) in Cardiovascular Patients in Guangdong Province" was formulated in order to provide a reference for the rational use of Paxlovid in clinical practice
.
Link:
https://guide.
medlive.
cn/guideline/27725
Novel coronavirus sense special population 01
Perinatal Newborn Novel Coronavirus Infection Prevention and Control Management Plan (3rd Edition)
In order to adapt to the new prevention and control needs, it is necessary to update the first and second versions of the perinatal neonatal novel coronavirus infection prevention and control management plan to better guide clinical practice
.
As a result, the Working Group has developed a third version of the plan
.
Link:
https://guide.
medlive.
cn/guideline/27603
Expert recommendations for the clinical treatment of severe novel coronavirus infection caused by the Omicron variant
The Critical Care Group of the Respiratory Disease Branch of the Chinese Medical Association and the Critical Care Medicine Expert Group of the Respiratory Disease Branch of the Chinese Medical Doctor Association jointly initiated and organized respiratory and critical care experts to write this recommendation based on the current evidence-based medical evidence and clinical practice, in order to standardize the clinical treatment
of critically ill patients.
Link:
https://guide.
medlive.
cn/guideline/27690
Coronavirus infection-related diseases 01
Definition of cough associated with new coronavirus infection and clinical diagnosis and treatment recommendations
Most patients will have cough after the new coronavirus infection, and current clinical observations show that the cough after the new coronavirus infection is more severe and persistent
than the cough caused by the common cold and seasonal influenza.
This article mainly introduces the definition of cough associated with new coronavirus infection and clinical diagnosis and treatment recommendations
.
Link:
https://guide.
medlive.
cn/guideline/27692
Brief Recommendations for the Diagnosis and Treatment of Myocarditis Associated with Novel Coronavirus Infection (1st Edition)
With the sharp increase in the number of new crown infections in China, the new coronavirus infection-related myocarditis has attracted widespread concern, if not diagnosed and properly treated in time, it may cause serious clinical consequences, in order to standardize the diagnosis and treatment of new coronavirus infection-related myocarditis, Beijing Tsinghua Chang Gung Hospital cardiovascular center put forward diagnosis and treatment suggestions
.
Link:
https://guide.
medlive.
cn/guideline/27682
Health and Nutrition Management 01
Expert Guidelines on Health Management for Persons Infected with Novel Coronavirus in the Recovery Period (First Edition)
This paper was formulated by experts organized by the Beijing Municipal Health Commission, bringing together the opinions of experts and scholars in different fields, summarizing relevant clinical experience, and aiming to help and guide the self-health management
of new coronavirus infected people in the recovery period.
Link:
https://guide.
medlive.
cn/guideline/27643
Expert consensus on home medicine health management for adults infected with novel coronavirus infection
This paper forms a consensus from the aspects of home environment, asymptomatic infection, mild infection, recovery period, and TCM non-drug therapy intervention, in order to guide the use of TCM intervention in patients infected with new coronavirus infection at home
.
Link:
https://guide.
medlive.
cn/guideline/27651
Recommendations for nutritional management of patients with novel coronavirus pneumonia
This guidance focuses on the nutrition management recommendations for adults and children with COVID-19, and provides reference
for the development of clinical nutrition diagnosis and treatment.
Link:
https://guide.
medlive.
cn/guideline/27637
